Chromatin Bioscience Partners with Purespring Therapeutics on Gene Therapy Research

Chromatin Bioscience has announced a research collaboration with Purespring Therapeutics to support the development of targeted genetic therapies for kidney diseases, announced in a press release.

The partnership will use Chromatin Bioscience’s proprietary chromatinLENS platform to design synthetic promoters that enable precise and durable gene expression in specific cell types. These cell-selective promoters are intended to improve the safety and efficacy of gene therapy delivery.

Purespring Therapeutics, a clinical-stage precision nephrology company, is developing genetic therapies that target podocytes through its GlomThera platform. The collaboration aims to integrate Chromatin’s synthetic promoter technology into Purespring’s therapeutic pipeline to enhance control of gene expression in kidney-targeted treatments.

While specific program details remain confidential, the collaboration represents an expansion of Chromatin Bioscience’s partnerships across the gene therapy sector.